06 Jan
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTOR™ Platform in Gene Therapy
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 alone – - Data support rapid advancement of Selecta’s gene therapy pipeline, including lead
04 Jan
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
WATERTOWN, Mass. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief